Brisbane, California-based Sangamo Therapeutics announced that Sanofi US was returning rights to SAR445136 as the Paris-based company shifts its approach from personalized cell therapies to allogeneic off-the-shelf genomic approaches.

Roche is launching a new genomic profiling kit that lets cancer researchers explore tumors without having to send tissue samples to centralized laboratories, the Swiss drugmaker said on Oct. 25.

Artificial Intelligence (AI) is at the forefront of modern technology and has begun to parallel in the world of biotechnology. Many biopharma companies are using AI to drive innovation, enhance their processes and explore new business models.

Britain said on July 7 the country would provide genomic sequencing support to Brazil, Ethiopia, Kenya, Nigeria and Pakistan to help identify, assess and track new variants of the novel coronavirus.

Britain agreed a partnership with the United States on Thursday to tackle new pandemics by bolstering disease surveillance and genomic sequencing worldwide, on the eve of a G7 leaders’ summit.

The Biden administration on April 16 said it will invest $1.7 billion to help states and the U.S. Centers for Disease Control and Prevention fight Covid-19 variants that are rapidly spreading across the United States.

XtalPi Inc., an AI-based pharmaceutical technology company with an AI-powered platform that twins with existing R&D pipelines, raised an additional $318.8 million through a Series C financing round to bring drug development into the future.

Switzerland’s Roche acquired genetic sequencing company Stratos Genomics for an undisclosed amount.

The U.S. Food and Drug Administration approved AstraZeneca and Merck’s Lynparza (olaparib) in combination with Roche’s Avastin (bevacizumab) for the maintenance treatment of adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer has been tested to have either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.

GRAIL published validation data for the company’s multi-cancer early detection blood test, which can detect more than 50 different cancer types across all stages.